Mirae Asset Global Etfs Holdings Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 184,041 shares of RNA stock, worth $8.67 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
184,041Holding current value
$8.67 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
226Shares Held
96.1MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$514 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$415 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$406 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$307 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$280 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.46B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...